Please Wait...

Biomarker Analysis

The use of biochemical markers as surrogate endpoints for measuring the effects of investigational compounds and monitoring disease progression has increased significantly over the last decade.

Bioclinica Lab has extensive experience with efficacy biomarkers, predictive biomarkers, and safety biomarkers. We offer more than 70 biochemical assays performed with manual and/or automated methods and determine the most suitable method for each biomarker according to performance and test kits. Our facilities are equipped with state of the art robotics and a dedicated laboratory space for performing radioactive assays. Using Multiplex technology, we offer our clients the ability to monitor several biomarkers in parallel.

Our biomarker assays include:
Radioimmunoassays (IRMA, RIA)
Multiplex (MagPix)
Our comprehensive biomarker panel
spans many therapeutic areas including:
Bone and Cartilage diseases
Cardiovascular disease
CNS diseases (Alzheimer's)
Infectious diseases
Inflammatory and Immunological diseases
Metabolic diseases (Diabetes)

All Bioclinica Lab assays are validated and qualified in-house according to a rigorous evaluation process and current international guidelines. We can also perform assay validation of customer-selected biomarkers or adapt assays to special biological matrices (e.g. synovial fluid or BALF).

Assay Validation

Bioclinica Lab validates each kit/method used for biomarker detection in a clinical study. Using assay validation, we objectively establish the reliability of a particular analytical method and ensure the accuracy and reliability of results.

A validation report summarizes the results of a test performance at Bioclinica Lab compared to manufacturer's data.

  • assay procedures
  • intra- and inter- assay variations, recovery, linearity and limits of detection
  • biomarker stability in a specific matrix for storage conditions and freeze-thaw cycles
  • expected values for population type (if data are available)


Prior to validation, we recommend a feasibility study to our clients for evaluating the potential of a method in a regulatory compliant environment. Bioclinica Lab will objectively qualify biomarker performance using a series of tests including dosage linearity and selectivity for a specific biomarker in a chosen matrix. At the end of a feasibility study, Bioclinica Lab will determine confidence in the chosen method and suitability for use in clinical trials.


Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Proud to sponsor & speak @vaccinenation World Congress! Hope to see you 4/4 in infectious disease #vaccines session…
bioclinica (3 hours ago)
RT @bioclinica: Excited for our Open House tomorrow (3/22)! #ASCPT2018 friends, still time to join us. Details here…
bioclinica (7 hours ago)
RT @bioclinica: Most sm. sponsors lack bandwidth for robust #pharmacovigilance @bioclinicaSVP tells @CenterWatch Maintaining an internal sa…
bioclinica (7 hours ago)
RT @bioclinica: Almost here! #ASCPT2018 Tour central Florida's premier Phase 1 facility at our Open House 3/22! Meet our team & see how @bi…
bioclinica (7 hours ago)
Most sm. sponsors lack bandwidth for robust #pharmacovigilance @bioclinicaSVP tells @CenterWatch Maintaining an int…
bioclinica (7 hours ago)
Excited for our Open House tomorrow (3/22)! #ASCPT2018 friends, still time to join us. Details here…
bioclinica (9 hours ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen